Material Agreement Form 8 K

Item 1.01 Entry Into a Material Definitive Agreement.

On November 29, 2024, ImmuCell Corporation (the "Company") entered into an Amending Agreement (the "Amendment") with Norbrook Laboratories Limited ("Norbrook"), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the "Agreement"). Pursuant to the Agreement, Norbrook provides certain formulation, aseptic filling and packaging services for the Company at its FDA-licensed facility in connection with the regulatory approval and subsequent commercial product sales of Re-Tain™, the Company's purified Nisin treatment for subclinical mastitis in lactating dairy cows. The Amendment provides, among other things, that Norbrook shall complete the manufacture of current in-process inventory and that the Agreement between the Company and Norbrook shall terminate on March 31, 2026 (subject to the terms of the Agreement).

The forgoing description of the Amendment is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 hereto and incorporated herein by this reference.